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S260 Poster Session IThere were 22 males, 18 females, ages 7 mo – 18.7 yrs, median 5.5
years. Stem cell sources for the msibs were marrow for 7 and PBSC
for 11. Conditioning regimen was fTBI based in 25, busulfan based
in 15–of those, 5 were reduced intensity. Graft-versus-host disease
prophylaxis included cyclosporin A and either methotrexate (n 5
35) or mycophenolate (n 5 5). Disease status at time of HSCT
was CR1 in 23, 11 were in CR2 and 6 had evidence of residual
AML (5% by morphology or [+] cytogenetics).
The median time to reach an ANC. 500/ml was 18 days (29 days
for UCB vs 12 after m/PBSC). An unsupported Plt Ct . 20,000/ml
was achieved in 36 pts at a median of 21 days (49 for UCB vs 13 after
m/PBSC). 4 UCB pts failed to engraft with donor hematopoiesis. 14
pts developed Gr II-IV acute GVHD, 8 of the 35 pts surviving more
than 100 days developed chronic GVHD (2 limited, 6 extensive). 9
UCB and 5 m/PBSC pts developed acute GVHD. 7 m/PBSC pa-
tients but only 1 UCB patient developed chronic GVHD.
Overall survival (OS) rates 3 years post HSCT were similar when
comparing UCB recipients (63%) versus combined matched m/
PBSC donors (78%), respectively. This result is despite the higher
proportion of CR2 and PR patients in the UCB cohort (64 vs
17%). OS of patients in CR1 and CR2 at the time of HSCT are
87 % and 43 % respectively.
Table 1. HSCT for Pediatric AML-msib v UCB
All pts, Matched UCB,
n540 sibs, n518 n522Male–Female 22–18 12–6 10–12
Age (yrs, median +/2 sd) 5.5 +/2 5.6 11.6 +/2 5.7 3.5 +/2 4.2
Weight (kg, median) 21 38 15
Diagnosis to HSCT (mo, median) 5.1 3.5 6.4
CR1 23 15 8
CR2 or PR 17 3 14fTBI-VP-CY 25 8 17
Bu4-CY+/2VP 10 6 4
Flu-Bu2 +/2 ATG 5 4 1ANC engraft (days, median) 18 12 29
Platelet engraft (days, median) 21 13 49
Non-engraft 4 4
TRM 5 1 4
Relapse 8 4 4
Overall Survival (%) 69 78 63Our experience supports continued consideration of allogeneic
HSCT for pediatric AML in CR1 utilizing matched sibling donors.
The results using unrelated UCB stem cell sources suggest that
young AML patients lacking a msib donor should search for an
UCB match and consider that option for HSCT in CR1. Methods
to enhance engraftment/limit rejection of UCB could potentially
further improve the results using UCB stem cells.291
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High dose chemotherapy with autologous hematopoietic stem cell
transplantation (HSCT) is the treatment of choice for relapsed or re-
fractory germ cell tumors (GCT) but few pediatric patients are in-
cluded in most reports. Our objective is to describe the
institutional experience with autologous HSCT for GCT.
Results: From November, 2001 to October, 2010, 11 patients with
GCT underwent HSCT after conditioning therapy with carboplatin
(425 mg/m2/day x 4 days), etoposide (337.5 mg/m2/day x 4 days) and
melphalan (70 mg/m2/day x 2 days) - doses for children older than 2
years of age and with normal renal function. Their median age was
12.5 years (2-19)and seven were female. One had primary centralnervous system (CNS) tumor, 6 gonadal and 4 extra-gonadal tumors.
Most patients had been treated according to the Brazilian GCTPro-
tocol-99 and received TIP – paclitaxel, ifosfamide and cisplatin as
second line chemotherapy. One patient was in the first remission
of a testicular tumor with trophoblastic component and multiple
brain and lung metastases; seven were in second remission; one
was in third remission and two had refractory disease with partial re-
sponse to therapy. All patients had a normal bone marrow aspirate
and biopsy prior to stem cell collection. Eight patients had periph-
eral blood stem cell harvest, one marrow, and one both, for a target
cell dose of 5 million CD34 cells/kg. All patients had febrile neutro-
penia (seven also had positive blood cultures), oral mucositis (all
needed IVmorphine) and diarrhea. One 3-year-old girl in second re-
mission had a CNS bleeding and died two months after HSCT. Five
patients had disease progression or relapse, three of them with ad-
vanced diseases. Five patients are alive in complete remission with
a median follow up of 6.8 years (2-8 years). In conclusion, GCT is
a rare indication of autologous HSCT in pediatrics (11/123 autolo-
gous transplants in 10 years). Despite acceptable results in adults
with refractory diseases, the best timing for autologous transplanta-
tion in pediatrics seems to be second remission. Carboplatin, etopo-
side and melphalan, the same regimen that has been used for many
years for stage 4 neuroblastoma, is associated with considerable tox-
icity but four of six evaluable patients with GCT in second remission
remain tumor-free more than six years after transplant.292
FLUDARABINE, BUSULFAN, AND ALEMTUZUMAB AS A REDUCEDTOXICITY
REGIMEN FOR CHILDREN WITH MARROW STEM CELL DEFECTS AND
MALIGNANCY IMPROVES ENGRAFTMENT AND GRAFT VERSUS HOST
DISEASE WITHOUT DELAYING IMMUNE RECONSTITUTION
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For many children with malignancies and MSCD, allogeneic he-
matopoietic cell transplant (HCT) provides the best chance of
cure. However, toxicity of conditioning and graft failure remain
challenges. We previously reported that busulfan, fludarabine and
rabbit ATG conditioning (total dose5 8mg/kg) resulted in less tox-
icity but no improvement in engraftment rates. Alemtuzumab has
been shown to enhance engraftment and reduce rates of GVHD in
myeloablative regimens. Thus, we prospectively evaluated targeted
IV busulfan, fludarabine and Alemtuzumab (total dose 5 1.5mg/
kg) in a Phase II study of children receiving closely matched related
or unrelatedHCT. Thirty-five children were enrolled: 5 with malig-
nancies and 30 withMSCD. Twelve donors were HLAmatched rel-
atives, 16 were fully HLA allele-matched unrelated donors and 7
were 9/10 HLA allele-matched unrelated donors. No patient had
more than a Grade 2 reaction to Alemtuzumab. The most common
toxicity (n 5 15) was Grade 3 mucositis. One patient had Grade 4
mucositis. Only 1 patient developed VOD (Grade 3). 11/15 CMV
seropositive patients had reactivation and 3/17 CMV seronegative
patients had primary CMV infection.None developedCMVdisease.
Thirty-one of 34 (88%) evaluable patients achieved durable engraft-
ment. Neutrophil recovery occurred at a median of 16 days (range
10-25). Three patients (2 mismatched at 1 antigen) with MSCD
failed to engraft from unrelated donor HCT and underwent subse-
quent transplants. One is alive and progression free. For those suc-
cessfully engrafted, the median time to CD4 . 200x10e6cells/L
and PHA . 50% was 6 months with a maximum of 9 months. At
1 year post transplant, 18/19 evaluable patients had 87%ormore do-
nor chimerism in whole blood, CD14/15+ and CD19+ subsets and
71% or more donor chimerism in the CD3+ subset. One patient
had only 55% whole blood donor chimerism at 1 year but ultimately
achieved 82%. Six patients developed acute Graft versus Host Dis-
ease (GVHD) of Grade 2-4 with only 1 patient progressing to
chronic GVHD. Seven patients had disease progression/relapse
with 1 dying from disease. Four patients died of Transplant Related
Mortality (11%). At a median follow up of 29 months (range 3-74),
the EFS was 60+/2 SE9% with an Overall Survival of 81+/
